Christian Hampp

12PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Disease surveillanceToxicology (incl. clinical toxicology)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 07, 2026
A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data.

|Jun 12, 2026
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.

|Apr 01, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.

Shaji Kumar, Katja C Weisel, Paul Spin

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Jun 05, 2023
Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System.

Amir Sarayani, Joshua D Brown, Christian Hampp

|Mar 20, 2023
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.

Amir Sarayani, William Troy Donahoo, Christian Hampp

Pageof 2

Frequent Collaborators

4 joint publications

Glenn S Kroog

4 joint publications

Alexander Breskin

3 joint publications

Almut G Winterstein

3 joint publications

Mostafa Shokoohi